Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Health Ministry Drafts...

Health Ministry Drafts Rule to Debar Pharma Applicants Submitting Fake or Misleading Documents

Written By : Susmita Roy Published On 2025-10-31T19:51:07+05:30  |  Updated On 31 Oct 2025 7:51 PM IST
Health Ministry Drafts Rule to Debar Pharma Applicants Submitting Fake or Misleading Documents

PRIP Scheme

  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: In a major regulatory move aimed at tightening compliance and accountability within India's pharmaceutical licensing framework, the Ministry of Health and Family Welfare (MoHFW) has issued draft rules to amend the Drugs Rules, 1945, introducing provisions for debarment of applicants found guilty of submitting fake, fabricated, or misleading documents.

The draft notification—G.S.R. 756(E), dated October 16, 2025 — was published by the Department of Health and Family Welfare, exercising powers under the Drugs and Cosmetics Act, 1940, after consultation with the Drugs Technical Advisory Board (DTAB).

The draft is published for the information of all persons likely to be affected thereby, and notice is given that the said draft rules shall be taken into consideration on or after the expiry of a period of thirty days from the date on which the copies of the Gazette of India containing these draft rules are made available to the public.

According to the proposal, new provisions titled “Debarment of applicant under this part” will be inserted across multiple sections of the Drugs Rules, including Rules 29B, 66B, 84F, 93A, 122DBA, 122Q, and 150L, empowering both Licensing Authorities and the Central Licensing Approving Authority to debar individuals or firms for a period deemed appropriate if found guilty of furnishing false or misleading information in connection with licensing, manufacturing, or related approvals.

The draft rules mandate that before issuing such an order, the concerned authority must give the applicant an opportunity to show cause and communicate the reasons in writing. Aggrieved applicants may appeal within thirty days to the respective government, which will conduct an inquiry and provide a hearing before passing a final order.

The Ministry has invited objections and suggestions from stakeholders within thirty days of the Gazette publication. Submissions may be sent to the Director (Drugs Regulation), MoHFW, at Room No. 407, A Wing, Nirman Bhavan, New Delhi – 110011, or emailed to drugsdiv-mohfw@gov.in

Following is the draft of certain rules further to amend the Drugs Rules, 1945, which the Central Government proposes to make, in exercise of the powers conferred by subsection (1) of section 12 and subsection (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), after consultation with the Drugs Technical Advisory Board.

Also Read: High-Alcohol Oral Drugs Over 12% to Come Under Prescription-Only H1 Category, Health Ministry Drafts Rules

DRAFT RULES

1. (i) These rules may be called the Drugs (...... Amendment) Rules, 2025.
(ii) These rules shall come into force at the time of final publication of the rules in the Official Gazette.
2. In the Drugs Rules, 1945, after the rule 29A following rule shall be inserted:
29B. Debarment of applicant under this part:
(1) Whoever himself or, any other person on his behalf, or applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/ information, may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Licensing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Licensing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such enquiry as it considers necessary, and after affording an opportunity of being heard, pass such orders as considered appropriate.
3. In the Drugs Rules, 1945, after the rule 66A following rule shall be inserted:
66B. Debarment of applicant under this part:
(1) Whoever himself, or any other person on his behalf, or applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/ information, may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Licensing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Licensing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such enquiry as it considers necessary, and after affording an opportunity of being heard, pass such orders as considered appropriate.
4. In the Drugs Rules, 1945, after rule 84E following rule shall be inserted:
84F. Debarment of applicant under this part:
(1) Whoever himself or, any other person on his behalf, or applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/ information, may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Central Licensing Approving Authority or Licencing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Central Licensing Approving Authority or Licencing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such enquiry as it considers necessary, and after affording an opportunity of being heard, pass such orders as considered appropriate.
5. In the Drugs Rules, 1945, after the rule 93 following rule shall be inserted:
93A. Debarment of applicant under this part:
(1) Whoever himself or, any other person on his behalf, or applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/ information, may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Central Licensing Approving Authority or Licencing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Central Licensing Approving Authority or Licencing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such enquiry as it considers necessary, and after affording an opportunity of being heard, pass such orders as considered appropriate.
6. In the Drugs Rules, 1945, after the rule 122DB following rule shall be inserted:
122 DBA. Debarment of applicant under this part: Whoever himself or, any other person on his behalf, or applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/ information, may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Licencing Authority for such period as deemed fit.
7. In the Drugs Rules, 1945, after the rule 122P following rule shall be inserted:
122Q. Debarment of applicant under this part:
(1) Whoever himself, or any other person on his behalf, or the applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/information may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Central Licensing Approving Authority or Licensing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Central Licensing Approving Authority or Licensing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such inquiry as it considers necessary and after affording an opportunity of being heard, pass such orders as are considered appropriate.
8. In the Drugs Rules, 1945, after the rule 150K following rule shall be inserted:
150L. Debarment of applicant under this part:
(1) Whoever himself, or any other person on his behalf, or the applicant is found to be guilty of submitting misleading, or fake, or fabricated documents/information may, after giving him an opportunity to show cause as to why such an order should not be made, in writing, stating the reasons thereof, be debarred by the Central Licensing Approving Authority or Licensing Authority for such period as deemed fit.
(2) Where an applicant is aggrieved by an order made by the Central Licensing Approving Authority or Licensing Authority under sub-rule (1), such applicant may, within thirty days from the receipt of the order, make an appeal to that Government and that Government, may, after such inquiry as it considers necessary and after affording an opportunity of being heard, pass such orders as are considered appropriate.
To view the official notice, click the link below:
https://medicaldialogues.in/pdf_upload/267196-306289.pdf
Also Read: UCPMP 2024: Govt Details Stricter Rules to Curb Gifts, Incentives from Pharma to Doctors
Drug Rule 1945Drug RulesDrug and Cosmetic Actdtabfake documentsmisleading documentsmohfwhealth ministrypharma firm
Susmita Roy
Susmita Roy

    Mpharm (Pharmacology)

    Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

    Show Full Article
    Next Story

    Editorial

    Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies

    Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies

    Indian Study Finds Vildagliptin SR Effective and Safe in Type 2 Diabetes Patients Uncontrolled on Metformin: PRIME-Vilda Trial

    Indian Study Finds Vildagliptin SR Effective and Safe in Type 2 Diabetes Patients Uncontrolled on...

    Advancements in Antifungal Treatment: Insights from In vitro Trials with Selenium Sulfide

    Advancements in Antifungal Treatment: Insights from In vitro Trials with Selenium Sulfide

    The Betami-Danblock Trial: Randomized Discontinuation Of Beta-Blockers After Myocardial Infarction

    The Betami-Danblock Trial: Randomized Discontinuation Of Beta-Blockers After Myocardial Infarction

    Reperfusion Therapy for STEMI in LMICs: A Clinical Consensus Discussion with Dr Thomas Alexander

    Reperfusion Therapy for STEMI in LMICs: A Clinical Consensus Discussion with Dr Thomas Alexander

    View All

    Journal Club Today

    Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies

    Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies

    View All

    Health News Today

    Health Bulletin 31/October/2025

    Health Bulletin 31/October/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok